S&P 500   2,999.20 (+0.11%)
DOW   26,806.87 (+0.07%)
QQQ   191.80 (-0.03%)
AAPL   242.45 (+1.04%)
FB   184.71 (+1.30%)
MSFT   135.91 (-0.34%)
GOOGL   1,250.40 (+0.74%)
AMZN   1,754.42 (-0.64%)
CGC   21.35 (+0.95%)
NVDA   195.18 (-0.22%)
MU   44.62 (-0.09%)
BABA   169.32 (-0.34%)
GE   9.12 (+0.55%)
TSLA   254.65 (-0.36%)
AMD   31.56 (+0.16%)
T   37.85 (-0.86%)
NFLX   272.60 (+2.22%)
BAC   31.30 (+0.32%)
GILD   66.30 (+0.67%)
DIS   131.03 (-1.04%)
S&P 500   2,999.20 (+0.11%)
DOW   26,806.87 (+0.07%)
QQQ   191.80 (-0.03%)
AAPL   242.45 (+1.04%)
FB   184.71 (+1.30%)
MSFT   135.91 (-0.34%)
GOOGL   1,250.40 (+0.74%)
AMZN   1,754.42 (-0.64%)
CGC   21.35 (+0.95%)
NVDA   195.18 (-0.22%)
MU   44.62 (-0.09%)
BABA   169.32 (-0.34%)
GE   9.12 (+0.55%)
TSLA   254.65 (-0.36%)
AMD   31.56 (+0.16%)
T   37.85 (-0.86%)
NFLX   272.60 (+2.22%)
BAC   31.30 (+0.32%)
GILD   66.30 (+0.67%)
DIS   131.03 (-1.04%)
Log in

DiaMedica Therapeutics Stock Price, News & Analysis (OTCMKTS:DMCAF)

Today's Range N/A
50-Day Range
$2.70
MA: $3.64
$4.96
52-Week Range N/A
Volume31,729 shs
Average Volume131,151 shs
Market Capitalization$565.70 million
P/E RatioN/A
Dividend YieldN/A
Beta-0.02
DiaMedica Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the development of treatments for neurological and kidney diseases. The company's lead product is DM199, a recombinant human tissue kallikrein-1 protein, which is in Phase II clinical trials for the treatment of acute ischemic stroke and kidney injury indications. It is also developing DM199 for the treatment vascular dementia. In addition, the company is developing DM300, which is in pre-clinical stage for the treatment for acute pancreatitis. The company was formerly known as DiaMedica Inc. and changed its name to DiaMedica Therapeutics Inc. in December 2016. DiaMedica Therapeutics Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolOTCMKTS:DMCAF
CUSIPN/A
CIKN/A
Phone763-496-5454

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

EmployeesN/A
Market Cap$565.70 million
Next Earnings DateN/A
OptionableNot Optionable

Receive DMCAF News and Ratings via Email

Sign-up to receive the latest news and ratings for DMCAF and its competitors with MarketBeat's FREE daily newsletter.


DiaMedica Therapeutics (OTCMKTS:DMCAF) Frequently Asked Questions

What is DiaMedica Therapeutics' stock symbol?

DiaMedica Therapeutics trades on the OTCMKTS under the ticker symbol "DMCAF."

Has DiaMedica Therapeutics been receiving favorable news coverage?

Media stories about DMCAF stock have been trending somewhat positive on Wednesday, according to InfoTrie Sentiment. The research group ranks the sentiment of news coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. DiaMedica Therapeutics earned a news impact score of 0.6 on InfoTrie's scale. They also gave media coverage about the company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an impact on the company's share price in the immediate future. View News Stories for DiaMedica Therapeutics.

Who are some of DiaMedica Therapeutics' key competitors?

What other stocks do shareholders of DiaMedica Therapeutics own?

Who are DiaMedica Therapeutics' key executives?

DiaMedica Therapeutics' management team includes the folowing people:
  • Mr. Rick Pauls MBA, CEO, Pres & Director (Age 47)
  • Dr. Todd A. Verdoorn Ph.D., Chief Scientific Officer
  • Mr. Scott B. Kellen, CFO & Company Sec. (Age 53)
  • Mr. Edward B. Rady, Chief Commercial Advisor (Age 69)
  • Dr. Dennis D. Kim M.D., MBA, Consulting Chief Medical Officer (Age 48)

How do I buy shares of DiaMedica Therapeutics?

Shares of DMCAF can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

How big of a company is DiaMedica Therapeutics?

DiaMedica Therapeutics has a market capitalization of $0.00. View Additional Information About DiaMedica Therapeutics.

What is DiaMedica Therapeutics' official website?

The official website for DiaMedica Therapeutics is http://www.diamedica.com/.

How can I contact DiaMedica Therapeutics?

DiaMedica Therapeutics' mailing address is 2 Carlson Parkway Suite 260, Minneapolis MN, 55447. The company can be reached via phone at 763-496-5454 or via email at [email protected]


MarketBeat Community Rating for DiaMedica Therapeutics (OTCMKTS DMCAF)

Community Ranking:  2.0 out of 5 (star star)
Outperform Votes:  25 (Vote Outperform)
Underperform Votes:  39 (Vote Underperform)
Total Votes:  64
MarketBeat's community ratings are surveys of what our community members think about DiaMedica Therapeutics and other stocks. Vote "Outperform" if you believe DMCAF will outperform the S&P 500 over the long term. Vote "Underperform" if you believe DMCAF will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 10/23/2019 by MarketBeat.com Staff

Featured Article: Outstanding Shares

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel